Envelope surface glycoprotein gp120
|
env
|
HIV-1 envelope protein gp120 is able to induce COX-2 mRNA and protein in human neuroblastoma cell lines that express CXCR4 and CCR5 but not CD4; gp120 induces COX-2 promoter transcription through NF-kappaB and activating protein-1 (AP-1) sites |
PubMed
|
|
env
|
Treatment of cells with HIV-1 gp120 induces increased levels of endogenous c-fos and c-jun mRNA and proteins, an activation of both c-fos and c-jun promoters, and a very rapid stimulation of the MAPK/ERK pathway |
PubMed
|
|
env
|
HIV-1 gp120 and anti-CD4 antibodies induce a specific, significant decrease in the binding activity of NF-AT, NF-kappa B and AP-1, which leads to an inhibition of IL-2 production and cell proliferation |
PubMed
|
|
env
|
Binding of heat-inactivated HIV-1 (iHIV-1) or HIV-1 gp120 to infected resting PBMCs is sufficient to activate NF-kappa B and AP-1, to induce cell surface expression of CD25, and to commit cells to produce virus |
PubMed
|
Envelope surface glycoprotein gp160, precursor
|
env
|
HIV-1 gp160 induces activation of transcription factor, activated protein-1 (AP-1), comprised of Fos and Jun proteins, in CD4 positive T cell lines |
PubMed
|
Nef
|
nef
|
Knockdown of C/EBPalpha, C/EBPgamma, and AP-1 by siRNA shows significant reduction of CCL5 levels, suggesting that C/EBPalpha, C/EBPgamma, and AP-1 proteins are involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
HIV-1 Nef expression in human (THP-1) monocyte-macrophages induces both DNA binding and transcriptional activities of the activator protein-1 (AP-1) transcription factor, c-fos and c-jun; this induction requires the proline-rich PxxP motif of Nef |
PubMed
|
|
nef
|
HIV-1 Nef inhibits the recruitment of AP-1 DNA binding activity by downregulating the transcription of c-fos in mitogen-stimulated human T cells |
PubMed
|
Tat
|
tat
|
HIV-1 Tat activates AP-1 (c-Jun/c-Fos) activity in human astroglioma cells |
PubMed
|
|
tat
|
HIV-1 Tat-mediated upregulation of CCL5 involves JAK2/3, AKT2/3, p38delta, NF-kappaB (p65/p50), C/EBP alpha/gamma, and AP-1 proteins |
PubMed
|
|
tat
|
Co-treatment of osteoblastic cells with HIV-1 Tat and RANKL/M-CSF upregulates c-fos expression and AP-1 activity |
PubMed
|
|
tat
|
The CKLF-like MARVEL transmembrane domain-containing family 2 (CMTM2) blocks HIV-1 Tat-induced AP-1 and CREB activation, which leads to suppress HIV-1 provirus transcription |
PubMed
|
|
tat
|
Transcription factors NFAT and AP-1 (c-Jun/c-Fos) are required for HIV-1 Tat-induced upregulation of COX-2 |
PubMed
|
|
tat
|
HIV-1 Tat expression in Jurkat T cells enhances cooperative NFAT/AP-1- but not AP-1-dependent transcription independent of its ability to transactivate the HIV-1 LTR |
PubMed
|
|
tat
|
HIV-1 Tat activates the AP-1 complex containing c-fos through a p56lck dependent mechanism |
PubMed
|
|
tat
|
HIV-1 Tat contributes to the super-induction of IL-2 promoter activity through transcription factors such as NF-kappaB and AP-1 (c-Jun and c-Fos) |
PubMed
|
|
tat
|
HIV-1 Tat upregulates c-Fos expression and c-Fos protein has been shown to be essential for optimal transactivation of the HIV-1 LTR promoter by Tat |
PubMed
|
Vpr
|
vpr
|
HIV-1 Vpr-induced upregulation of CCL5 requires p50 and p65 subunits of NF-kappaB, p38delta MAPK, Akt-2 and Akt-3, and AP-1 transcription factor in HIV-1 Vpr transfected astrocytes |
PubMed
|
|
vpr
|
Synthetic HIV-1 Vpr protein activates AP-1 (Jun/Fos), c-Jun N-terminal kinase (JNK), NF-kappaB, and MKK7 in both U937 cells and primary macrophages. |
PubMed
|
Vpu
|
vpu
|
HIV-1 Vpu-expressing U937 monocytes coculture with LX2 stellate cells to activate release of transforming growth factor beta to culture supernatant, which correlates with increased activity of the AP-1 transcription factor |
PubMed
|
matrix
|
gag
|
HIV-1 matrix activates monocytes to produce MCP-1, which depends on the binding activity of AP-1 complexes (c-Fos/JunB) in the MCP-1 promoter |
PubMed
|